Brivanib

Brivanib : ATP competitive inhibitor of KDR

Structure

SERP Rating

In Cells

(1 ratings)

In Model Organisms

(1 ratings)

note: The Chemical Probes Portal only endorses compounds as chemical probes for use as specific and selective modulators of the proposed target if they receive three or more (3-4) stars.

Probe Brivanib is in the process of SERP review.

Please continue to check back for new reviews and commentary.

Information

ATP competitive

up to 10 uM
Reviewer recommended concentration: 1 µM

More...

Probe Availability:

In Vitro Validations

Uniprot ID: P35968

Target Class: Kinase

Target SubClass: TK

Potency: IC50

Potency Value: 26 nM

Potency Assay: Kinase Assay using [γ-33P]-ATP IC50; 25 nM Ki

PDB ID for probe-target interaction (3D structure): --

Structure-activity relationship: yes

Target aliases:

Vascular endothelial growth factor receptor 2, VEG ...

DOI Reference: 10.1021/jm051106d

Uniprot ID: P35968

Target Class: Kinase

Target SubClass: TK

Potency: Ki

Potency Value: 25 nM

Potency Assay: Kinase Assay using [γ-33P]-ATP

PDB ID for probe-target interaction (3D structure): --

Target aliases:

Vascular endothelial growth factor receptor 2, VEG ...

DOI Reference: 10.1021/jm051106d

In Cell Validations

In Vivo Data

Off-Target Selectivity Assesments

Potency end-point : IC50 FLK1 89 nM, FGFR1 148 nM

Probe Selectivity in Vitro:

Kinase Selectivity IC50 (nM): VEGFR-1 380, FGFR-1 148, PDGFR-β >6000, EGFR >1900, LCK >2500, PKCα >25000, JAK-3 >50000

I have extra information to add

SERP ratings and comments

SERP Ratings

In Cell Rating

In Model Organisms

SERP Comments:

Brivanib (BMS-540215) is a potent ATP-competitive inhibitor of KDR (VEGFR2) kinase. Due to limited selectivity data (only KDR plus seven additional kinases were tested), additional data would be necessary before considering this compound as a tool compound.

(last updated: 19 Oct 2025 )